TE
Tema ETFs Portfolio holdings
AUM
$377M
This Quarter Return
-2.81%
1 Year Return
–
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$335M
AUM Growth
+$335M
(+39%)
Cap. Flow
+$106M
Cap. Flow
% of AUM
31.69%
Top 10 Holdings %
Top 10 Hldgs %
28.51%
Holding
174
New
26
Increased
81
Reduced
34
Closed
27
Top Buys
| 1 |
Terex
TEX
|
$5.48M |
| 2 |
Herc Holdings
HRI
|
$4.98M |
| 3 |
Bristol-Myers Squibb
BMY
|
$4.58M |
| 4 |
Timken Company
TKR
|
$4.49M |
| 5 |
Eli Lilly
LLY
|
$4.13M |
Top Sells
| 1 |
Primoris Services
PRIM
|
$7.13M |
| 2 |
Fluor
FLR
|
$5.32M |
| 3 |
Federal Signal
FSS
|
$5.11M |
| 4 |
Alnylam Pharmaceuticals
ALNY
|
$2.66M |
| 5 |
Ascendis Pharma
ASND
|
$2.02M |
Sector Composition
| 1 | Industrials | 43.38% |
| 2 | Healthcare | 33.02% |
| 3 | Utilities | 7.31% |
| 4 | Technology | 5.91% |
| 5 | Financials | 4.26% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
126
Biogen
BIIB
$19.4B
| $342K | 0.1% |
2,501
| – | – |
|
127
Schrodinger
SDGR
$1.44B
| $325K | 0.1% |
16,457
-18,331
| -53% | -$362K |
|
128
Incyte
INCY
$16.5B
| $305K | 0.09% |
5,042
-25,336
| -83% | -$1.53M |
|
129
Stryker
SYK
$150B
| $297K | 0.09% |
798
| – | – |
|
130
Cullinan Oncology
CGEM
$445M
| $296K | 0.09% |
39,164
+10,731
| +38% | +$81.2K |
|
131
Illumina
ILMN
$15.8B
| $279K | 0.08% |
3,513
-10,726
| -75% | -$851K |
|
132
Catalyst Pharmaceutical
CPRX
$2.52B
| $275K | 0.08% |
11,352
| – | – |
|
133
Axsome Therapeutics
AXSM
$6.05B
| $271K | 0.08% |
+2,327
| New | +$271K |
|
134
Arvinas
ARVN
$568M
| $269K | 0.08% |
38,315
+26,480
| +224% | +$186K |
|
135
Syndax Pharmaceuticals
SNDX
$1.41B
| $260K | 0.08% |
+21,169
| New | +$260K |
|
136
Rocket Pharmaceuticals
RCKT
$354M
| $246K | 0.07% |
36,863
-54,122
| -59% | -$361K |
|
137
Relay Therapeutics
RLAY
$619M
| $233K | 0.07% |
89,110
+24,455
| +38% | +$64.1K |
|
138
Oric Pharmaceuticals
ORIC
$994M
| $228K | 0.07% |
40,934
-4,542
| -10% | -$25.3K |
|
139
Denali Therapeutics
DNLI
$2.23B
| $206K | 0.06% |
+15,174
| New | +$206K |
|
140
Xenon Pharmaceuticals
XENE
$2.98B
| $205K | 0.06% |
6,111
| – | – |
|
141
Intellia Therapeutics
NTLA
$1.22B
| $189K | 0.06% |
26,537
-121,630
| -82% | -$865K |
|
142
Acadia Pharmaceuticals
ACAD
$4.38B
| $176K | 0.05% |
10,596
| – | – |
|
|
AUTL
143
Autolus Therapeutics
AUTL
$399M
| $171K | 0.05% |
+110,428
| New | +$171K |
|
144
Celcuity
CELC
$2.17B
| $158K | 0.05% |
+15,619
| New | +$158K |
|
145
Arcus Biosciences
RCUS
$1.13B
| $120K | 0.04% |
15,251
-6,982
| -31% | -$54.8K |
|
146
Talkspace
TALK
$445M
| $71.3K | 0.02% |
27,834
+1,497
| +6% | +$3.83K |
|
147
Voyager Therapeutics
VYGR
$186M
| $50.6K | 0.02% |
14,960
| – | – |
|
148
Advanced Energy
AEIS
$5.65B
| – | – |
-3,528
| Closed | -$408K |
|
149
Agios Pharmaceuticals
AGIO
$2.19B
| – | – |
-25,735
| Closed | -$846K |
|
150
Argan
AGX
$3.11B
| – | – |
-1,792
| Closed | -$246K |
|